What is ProPhase Labs?
Established in 1989 and headquartered in Doylestown, Pennsylvania, ProPhase Labs has cultivated a robust reputation for its expertise in consumer healthcare products and dietary supplements. The company operates at the intersection of medical science and retail health, providing essential wellness solutions to a broad consumer base. Through its diversified portfolio, ProPhase Labs maintains a strategic focus on product innovation and market expansion, ensuring that its offerings remain relevant in an evolving healthcare environment. The company's ability to navigate complex regulatory landscapes while maintaining consistent product quality has been a cornerstone of its operational success for over three decades.
How much funding has ProPhase Labs raised?
ProPhase Labs has raised a total of $63.7M across 7 funding rounds:
Debt
$1.5M
Debt
$10M
Stock Offering
$37.5M
Multiple Rounds
$14.7M
Debt (2015): $1.5M, investors not publicly disclosed
Debt (2020): $10M, investors not publicly disclosed
Stock Issuance/Offering (2021): $37.5M, investors not publicly disclosed
Debt (2025): $1M, investors not publicly disclosed
Debt (2025): $3M, investors not publicly disclosed
Debt (2025): $3M, investors not publicly disclosed
Other Financing Round (2025): $7.7M led by Keystone Capital Partners
Key Investors in ProPhase Labs
Keystone Capital Partners
Keystone Capital Partners is a New York City-based investment firm that provides tailor-made solutions to facilitate long-term growth for companies. The firm specializes in helping overlooked businesses achieve their full potential through strategic financial support.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for ProPhase Labs?
With the recent injection of capital, ProPhase Labs is well-positioned to execute its next phase of strategic development. The company is expected to prioritize the enhancement of its supply chain capabilities and the expansion of its research and development initiatives. By focusing on high-growth segments within the dietary supplement market, the firm intends to capitalize on shifting consumer preferences toward preventative health and wellness. Furthermore, the strategic backing provided by its investment partners will likely facilitate deeper market penetration and the potential for future product diversification, ensuring that ProPhase Labs remains a formidable player in the medical science industry as it scales its enterprise-level operations.
See full ProPhase Labs company page
